How do you pay?

How to pay the least

Ask for the cash price

Hyrnuo

We didn’t find one.

  1. Ask your pharmacy for Hyrnuo’s cash price, and one or two other pharmacies too.
  2. Hyrnuo’s savings card works only with insurance from a job or one you bought.

Compare every option

Question
Brand nameHyrnuo
Authorized genericsevabertinib
Regular genericsevabertinib
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Hyrnuo?
The original
–
–

Brand nameThe maker’s card

HYRNUO $0 Co-Pay Program

Savings card from Bayer

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a month

Sign up on hyrnuo-us.com 

Or call 1-833-423-5561.

In the maker’s words

“Patients are eligible if they are commercially insured and may pay as little as $0 per month.”

From the maker’s offer on hyrnuo-us.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Hyrnuo itself, from the same company, sold without the brand name, and usually for less. For now Hyrnuo is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

HYRNUO is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.

This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Source: the FDA label for Hyrnuo (Bayer HealthCare Pharmaceuticals Inc.), September 17, 2026. Full label on DailyMed 

Good to know